(PBH) Prestige Consumer Healthcare Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PBH) Prestige Consumer Healthcare Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Prestige Consumer Healthcare Inc. BCG Matrix is a simple strategic tool used to classify the company’s products or business units into Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can see the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Hydralyte, oral rehydration, international expansion
Hydralyte fits a Star: it plays in oral rehydration, hydration, wellness, and recovery, while Prestige Consumer Healthcare Inc. keeps widening U.S. distribution beyond its core international base. In fiscal 2025, Prestige generated about $250 million in net sales, and Hydralyte remains one of its clearest growth bets. That mix of category demand and expansion supports Star-style portfolio treatment.
TheraTears, dry-eye care, screen-time demand
TheraTears sits in a growth pocket because screen use keeps dry-eye demand high; U.S. adults spend about 7 hours a day on screens, which sustains treatment need. Its premium eye-care position supports pricing power, but it still needs steady marketing and shelf support to defend share, which fits a Star profile.
DenTek, interdental care, oral-health growth
DenTek fits Prestige Consumer Healthcare's Star logic because it sits in oral-care adjacencies where preventive use is still underpenetrated; U.S. dental spending was about $177 billion in 2024, and preventive products get more dentist support each year. Prestige reported fiscal 2025 net sales of about $1.1 billion, giving room to keep scaling DenTek with merchandizing and line extensions. The brand can ride dentist-recommended interdental care and expand faster than the core.
Debrox, earwax removal, self-care category
Debrox fits Star logic because it is a recognized at-home earwax removal brand in a self-care category that people keep buying. Prestige Consumer Healthcare Inc. reported fiscal 2025 net sales of about $1.12 billion, and this kind of steady OTC demand helps support investment in brands with repeat use. Ear care is niche, but Debrox has enough brand pull to defend share and keep growing.
- Recognized self-care brand
- Fits at-home treatment demand
- Steady, not giant, category
- Enough traction for investment
Boudreaux's Butt Paste, diaper rash care, baby segment
Boudreaux's Butt Paste is one of Prestige Consumer Healthcare Inc.'s best-known baby-care brands, and diaper rash care is a repeat-use need that supports steady shelf demand. In FY2025, Prestige generated about $1.1 billion in net sales, so a trusted premium baby line can still add value through distribution gains and brand loyalty. If Prestige keeps defending share, Boudreaux's can stay a stable Stars-style asset in the baby segment.
- Recurring need supports repeat purchases.
- Trust and shelf space drive growth.
- Share defense keeps the brand strong.
Prestige’s Star Brands Drive Repeat OTC Growth
Stars in Prestige Consumer Healthcare Inc.’s mix are Hydralyte, TheraTears, DenTek, Debrox, and Boudreaux's Butt Paste because they sit in repeat-use care niches with room to gain share. Fiscal 2025 net sales were about $1.1 billion to $1.12 billion, and that scale supports brand spend and shelf gains. Hydralyte and TheraTears lean on rising hydration and dry-eye demand, while DenTek, Debrox, and Boudreaux's benefit from steady OTC repurchase.
| Brand | Star driver | FY2025 cue |
|---|---|---|
| Hydralyte | Hydration, recovery | Growth bet |
| TheraTears | Dry-eye demand | Premium position |
| DenTek | Oral-care adjacency | Expand share |
| Debrox | Repeat OTC use | Defend brand |
What is included in the product
Detailed Word Document
Prestige Consumer Healthcare’s BCG Matrix maps its brands into Stars, Cash Cows, Question Marks, and Dogs to guide invest/hold/divest decisions.
Editable Excel File
Quick BCG view of Prestige Consumer Healthcare Inc. to spot cash cows and weak spots fast.
Reference Sources
Lists trusted sources for Prestige Consumer Healthcare Inc., making the analysis easier to verify, defend, and use for faster decisions.
Cash Cows
Clear Eyes, eye redness relief, mature shelf staple
Clear Eyes is a long-running OTC eye-drop brand with strong shelf recognition and steady repeat use. In Prestige Consumer Healthcare's FY2025, net sales were about $1.1 billion, and mature eye-care brands like Clear Eyes help fund growth elsewhere. With limited category growth but durable awareness, Clear Eyes fits the Cash Cow slot.
Monistat, antifungal treatment, category leader
Monistat is a category leader in vaginal antifungal care, and its repeat-use model fits a Cash Cow. Prestige Consumer Healthcare Inc. reported roughly $1.1 billion in fiscal 2025 net sales, with mature brands like Monistat helping support steady cash generation. Because the category is stable and low-growth, Prestige can harvest cash without heavy growth spend.
Dramamine, motion sickness, travel staple
Dramamine is Prestige Consumer Healthcare Inc.'s classic motion-sickness cash cow, with steady demand tied to travel, not fast category growth. In fiscal 2025, Prestige Consumer Healthcare Inc. generated about $1.1 billion in net sales, and brands like Dramamine help support that cash flow with modest promotion. As travel volumes hold up, this franchise stays a low-drama, repeat-purchase brand.
Compound W, wart removal, steady OTC demand
Compound W is a long-standing wart-removal brand with broad household recognition, so it fits a Cash Cow role in Prestige Consumer Healthcare’s BCG mix. Wart care is a small, mature OTC niche, which limits growth but supports steady repeat demand and dependable cash flow. That means the brand needs far less heavy investment than newer growth bets.
- Legacy brand, high awareness
- Mature OTC niche, low growth
- Steady demand, strong cash generation
BC/Goody's, analgesic powders, legacy pain relief
BC and Goody's are legacy OTC analgesic powders in a mature U.S. pain-relief market, so they fit the Cash Cow slot: steady repeat use, strong brand recall, and limited growth. Prestige Consumer Healthcare posted about $1.14 billion in fiscal 2025 net sales, and these brands help support that cash flow even as category growth stays low. Their role is defensive, not expansion-led.
- High repeat purchase
- Strong historical awareness
- Low growth, high cash yield
Prestige’s OTC Cash Cows: Steady Brands, Steady Cash
Prestige Consumer Healthcare Inc.’s Cash Cows are mature OTC brands that keep selling with little growth spend. In fiscal 2025, the Company generated about $1.1 billion in net sales, and brands like Clear Eyes, Monistat, Dramamine, Compound W, and BC and Goody's helped turn steady demand into cash. Their low-growth niches make them reliable profit engines, not expansion bets.
| Brand | Cash Cow fit | Why |
|---|---|---|
| Clear Eyes | High | Strong awareness, repeat use |
| Monistat | High | Category leader, steady demand |
| Dramamine | High | Travel-linked, mature niche |
Get Your Copy
Prestige Consumer Healthcare Inc. Reference Sources
The Prestige Consumer Healthcare Inc. BCG Matrix preview you’re viewing is the exact same file you’ll receive after purchase. No demo content, no watermarks—just the complete, ready-to-use report. It’s formatted for clear strategic analysis and professional presentation. Once purchased, the full document is instantly available for download.
Dogs
Luden's, cough lozenges, small OTC share
Luden's is a small OTC brand in a crowded cough and cold aisle, with no public sign of strong share gain. Prestige Consumer Healthcare reported FY2025 net sales of about $1.15 billion, but it does not break out Luden's sales, which suggests limited scale. With weak growth momentum and shelf pressure from larger rivals, Luden's fits BCG Dog status.
Fess, saline nasal wash, niche international
Fess is a niche saline nasal wash with limited scale outside Prestige Consumer Healthcare Inc.’s core markets. In nasal care, brands face easy switching and heavy competition from large OTC players, so weak share and slow growth fit Dog status. Prestige Consumer Healthcare Inc. places it in a low-growth, low-share corner of the BCG matrix.
Nix, lice treatment, shrinking category
Nix sits in a shrinking, low-growth lice-treatment niche, so it is not a major growth engine for Prestige Consumer Healthcare Inc. Head lice cases are episodic, not steady, and the CDC estimates 6 million to 12 million U.S. infestations a year in children ages 3-11, which makes demand choppy and highly seasonal. With easy OTC substitutes and heavy price pressure, Nix is more of a weak cash contributor than a durable winner.
Gaviscon, antacid care, crowded competition
Gaviscon sits in a crowded antacid aisle where price and brand familiarity drive most buys, so it faces pressure from cheaper store brands and bigger names like Tums and Pepcid. That keeps growth muted and share limited in key markets, making it a weaker BCG candidate versus Prestige Consumer Healthcare Inc.’s stronger brands.
- High shelf clutter
- Price-sensitive switching
- Low share, low growth
Summer's Eve, feminine hygiene wash, low growth
Summer's Eve is a mature feminine-hygiene brand in a steady, low-growth category, so it fits Prestige Consumer Healthcare Inc.'s Dog quadrant more than the growth buckets. With no clear share advantage, the brand’s upside is limited versus faster-moving lines. In FY2025, this kind of flat-demand franchise usually gets held for cash, not expansion.
- Low growth limits new upside
- Mature brand, weak share edge
- Best viewed as cash-generative
Prestige’s Dogs: Low-Share Brands Stuck in Slow-Growth Markets
Prestige Consumer Healthcare Inc.’s Dogs are low-share, low-growth brands that mostly throw off cash, not expansion. FY2025 net sales were about $1.15 billion, but Luden's, Fess, Nix, Gaviscon, and Summer's Eve were all in crowded, mature niches with weak growth. That makes them the weakest BCG fit in the portfolio.
| Brand | Dog cue |
|---|---|
| Luden's | Small OTC share |
| Fess | Niche saline use |
| Nix | Choppy demand |
Question Marks
Chloraseptic, sore-throat sprays, seasonal upside
Chloraseptic has strong shelf recognition, but sore-throat demand still swings with cold and flu season, so sales are uneven. Prestige Consumer Healthcare reported about $1.1 billion in FY2025 net sales, but this brand still needs a bigger share of that base through better retail visibility and line extensions. Until those gains show up, Chloraseptic fits the Question Mark box: decent awareness, limited growth proof.
Fleet, bowel-care extensions, aging-demand tailwind
Fleet is a Question Mark because bowel-care demand should rise with aging: the U.S. had about 62 million people age 65+ in 2025, and older adults use laxatives more often. Prestige can benefit from self-care habits, but Fleet sits in a fragmented market with strong store brands and OTC rivals. Growth depends on widening share, not just category tailwind.
Hydralyte U.S. retail buildout, low current penetration
Hydralyte has stronger traction in Australia and other international markets, but its U.S. retail base is still small. The U.S. hydration and electrolyte market is a multibillion-dollar category, so even low share can turn into meaningful upside for Prestige Consumer Healthcare Inc. if distribution expands. That gap makes Hydralyte a classic Question Mark: high market potential, but still limited U.S. penetration and an open path to win share.
TheraTears Preservative-Free, premium eye-care line
TheraTears Preservative-Free sits in a Question Mark spot: preservative-free dry-eye care is a growth niche, and dry eye affects over 38 million U.S. adults. If premium formats keep gaining share, this line can scale fast, but right now it still lacks the volume to be a Star for Prestige Consumer Healthcare Inc.
- Growth niche, but small base
- Premium adoption can lift sales
- Needs more scale before Star status
DenTek aligner-care and whitening extensions, adjacent oral care
DenTek’s aligner-care and whitening lines fit adjacent oral care: they meet faster-growing needs, but DenTek still lacks clear category leadership. Prestige Consumer Healthcare may need heavier spend on shelf space, ads, and innovation to turn these into BCG "question marks" into winners.
- Growing demand, weak share
- Needs brand and shelf investment
- Upside if repeat buys rise
Prestige’s Question Mark Brands Need Share Gains to Move the Needle
Chloraseptic, Fleet, Hydralyte, TheraTears Preservative-Free, and DenTek are Question Marks: each has clear demand, but Prestige Consumer Healthcare Inc. has not yet turned that into category-leading share. In FY2025, Prestige Consumer Healthcare Inc. posted about $1.1 billion in net sales, so these brands need share gains to move the needle.
| Brand | Why it is a Question Mark |
|---|---|
| Chloraseptic | Strong awareness, seasonal demand |
| Fleet | Older population helps, share is weak |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.